BCR and acute lymphoblastic leukemia: Previous studies suggest that mutations in the BCR-ABL1 tyrosine kinase domain can cause relapse in Ph+ ALL mouse models treated with BCR-ABL1-targeted TKIs like imatinib 2, 48.